Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUT7 | Q11130 | 1/20 | 0.49 |
| ▸ | GPR35 | Q9HC97 | 6/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38664548 | 0.84 | POLB (0.46) | GPR35ALOX15ALDH1A1CA12CA1 | |
| SCHEMBL11206702 | 0.83 | ESR1 (0.57) | FUT7GPR35ESR1 | |
| SCHEMBL11204852 | 0.83 | ESR1 (0.57) | FUT7GPR35ESR1 | |
| SCHEMBL8733612 | 0.83 | ESR1 (0.57) | FUT7GPR35ESR1 | |
| SCHEMBL1861075 | 0.83 | ESR1 (0.57) | FUT7GPR35ESR1 | |
| SCHEMBL17965860 | 0.80 | GPR35 (0.48) | FUT7GPR35ALOX15ALOX12ALDH1A1 | |
| SCHEMBL30628004 | 0.80 | GPR35 (0.48) | FUT7GPR35ALOX15ALOX12ALDH1A1 | |
| SCHEMBL28292691 | 0.80 | GPR35 (0.57) | GPR35ESR1ALOX15ALOX12ALDH1A1 | |
| SCHEMBL8736399 | 0.79 | GPR35 (0.53) | GPR35ESR1CRHBPCRHR2ALDH1A1 | |
| Trinitrophenol SCHEMBL28189803 | 0.78 | GPR35 (0.46) | GPR35ALOX15ALOX12ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7635722-B1 | Chemical induced intracellular hyperthermia | Saint Jude Pharmaceuticals, Inc. (US) | 2009-12-22 | — | — | US | disclosed |
| EP-0412211-A1 | Cancer therapy system | THERAPEUTICAL SYSTEMS CORPORATION (US) | 1991-02-13 | — | — | EP | disclosed |
| US-4935450-A | Cancer therapy system for effecting oncolysis of malignant neoplasms | THERAPEUTICAL SYSTEMS CORPORATION (US) | 1990-06-19 | — | — | US | disclosed |
| US-4724234-A | ADMINISTERING NUTRITIONAL REGIMEN AND AGENTS WHICH UNCOUPLE OXIDATIVE PHOSPHORYLATION | THERAPEUTICAL SYSTEMS CORP. (US) | 1988-02-09 | — | — | US | disclosed |